The Reserve Bank of India's (RBI's) mid-quarter monetary policy review and the US Federal Reserve's meeting which could take a call on tapering its 85-billion-a-month bond buying program, would be the key triggers for market this week.
The Fed will hold its two-day Federal Open Market Committee (FOMC) meeting on Tuesday and Wednesday to decide on the timeline for scaling back its monthly bond buying program also known as quantitative easing-3 (QE-3).
Wholesale inflation or Wholesale Price Indexed-inflation surged to 14-month high of 7.52% in the month of November sparking off fears of a potential repo rate hike by the RBI in its forthcoming policy meet on December 18. Earlier, consumer price-indexed inflation (CPI) or retail inflation rose to a nine-month high of 11.24% in November, prompting many to think that RBI could raise repo rates by 25bps to check the inflation.
The US central bank is expected to decide a timeline for scalback of its stimulus package, termed Quantitative Easing-3. The signs of improvement in US economic data could see Fed announcing a withdrawal or a reduction in its $85-billion bond-buying programme at the FOMC meet.
So, both the above factors are being viewed as potential sell-off triggers. In such a scenario what stocks are placed in favourable position on techincal parameters?
SmartInvestor : Investors are jittery ahead of key data lined ahead. What are the levels to watch out benchmarks. Is it ok to go long at current levels?
AK Prabhakar : Both Nifty & Sensex has made all time high last week post which we have seen 4-5days of correction and i am positive of market till 5950 on lower side is not breached then target of 7000-7200 in next few months becomes possible. For next few weeks if 6141 holds and above 6200 then 6450 is target in 5-6days.
SmartInvestor : What is your take on GSK Pharma today? Should investors tender and how is the stock looking on technical parameters?
AK Prabhakar : GSKPHARMA has made all time high today and i feel stock has potential to cross Rs.3200 very soon.
SmartInvestor : Metal stocks are in focus after latest Chinese econmic data. Your take on Tata Steel ans SSLT. Your top picks from there?
The Fed will hold its two-day Federal Open Market Committee (FOMC) meeting on Tuesday and Wednesday to decide on the timeline for scaling back its monthly bond buying program also known as quantitative easing-3 (QE-3).
Wholesale inflation or Wholesale Price Indexed-inflation surged to 14-month high of 7.52% in the month of November sparking off fears of a potential repo rate hike by the RBI in its forthcoming policy meet on December 18. Earlier, consumer price-indexed inflation (CPI) or retail inflation rose to a nine-month high of 11.24% in November, prompting many to think that RBI could raise repo rates by 25bps to check the inflation.
The US central bank is expected to decide a timeline for scalback of its stimulus package, termed Quantitative Easing-3. The signs of improvement in US economic data could see Fed announcing a withdrawal or a reduction in its $85-billion bond-buying programme at the FOMC meet.
So, both the above factors are being viewed as potential sell-off triggers. In such a scenario what stocks are placed in favourable position on techincal parameters?
SmartInvestor : Investors are jittery ahead of key data lined ahead. What are the levels to watch out benchmarks. Is it ok to go long at current levels?
AK Prabhakar : Both Nifty & Sensex has made all time high last week post which we have seen 4-5days of correction and i am positive of market till 5950 on lower side is not breached then target of 7000-7200 in next few months becomes possible. For next few weeks if 6141 holds and above 6200 then 6450 is target in 5-6days.
SmartInvestor : What is your take on GSK Pharma today? Should investors tender and how is the stock looking on technical parameters?
AK Prabhakar : GSKPHARMA has made all time high today and i feel stock has potential to cross Rs.3200 very soon.
SmartInvestor : Metal stocks are in focus after latest Chinese econmic data. Your take on Tata Steel ans SSLT. Your top picks from there?
Click here for more...
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%